Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
The British Journal of Dermatology
|
July 8, 2015
Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exercise
E Healy, S J Brown, S M Langan, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
November 2, 2019
Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Makoto Aihara, Fenghe Lu, Hisashi Kawata, et al.
Journal of Glaucoma
|
March 7, 2019
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Makoto Aihara, Fenghe Lu, Hisashi Kawata, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
January 15, 2020
Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells
Yasuko Yamamoto, Takazumi Taniguchi, Tomoaki Inazumi, et al.
Mymensingh Medical Journal : MMJ
|
October 1, 2024
Evaluating the Acceptance and Awareness of GPT-Based AI for Health Assistance in Clinical Practice among Registered Physicians of Bangladesh
M N H Nishan, S M K Shams, M N U Ahmed, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
February 18, 2021
Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Masahiro Fuwa, Atsushi Shimazaki, Noriko Odani-Kawabata, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
May 16, 2020
The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice
Yoshihiko Esaki, Osamu Katsuta, Hitomi Kamio, et al.
American Journal of Ophthalmology
|
December 4, 2003
Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis
Jack V Greiner, Thomas Mundorf, Harvey Dubiner, et al.
The British Journal of Dermatology
|
April 23, 2014
Management of morphoea: results of a national survey of U.K. clinicians
K L Warburton, M J McPhee, L J Savage, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)
|
October 19, 2016
SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line
M Seifi-Najmi, M Hajivalili, R Safaralizadeh, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
The British Journal of Dermatology
|
July 8, 2015
Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exercise
E Healy, S J Brown, S M Langan, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
November 2, 2019
Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Makoto Aihara, Fenghe Lu, Hisashi Kawata, et al.
Journal of Glaucoma
|
March 7, 2019
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Makoto Aihara, Fenghe Lu, Hisashi Kawata, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
January 15, 2020
Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells
Yasuko Yamamoto, Takazumi Taniguchi, Tomoaki Inazumi, et al.
Mymensingh Medical Journal : MMJ
|
October 1, 2024
Evaluating the Acceptance and Awareness of GPT-Based AI for Health Assistance in Clinical Practice among Registered Physicians of Bangladesh
M N H Nishan, S M K Shams, M N U Ahmed, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
February 18, 2021
Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Masahiro Fuwa, Atsushi Shimazaki, Noriko Odani-Kawabata, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
May 16, 2020
The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice
Yoshihiko Esaki, Osamu Katsuta, Hitomi Kamio, et al.
American Journal of Ophthalmology
|
December 4, 2003
Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis
Jack V Greiner, Thomas Mundorf, Harvey Dubiner, et al.
The British Journal of Dermatology
|
April 23, 2014
Management of morphoea: results of a national survey of U.K. clinicians
K L Warburton, M J McPhee, L J Savage, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)
|
October 19, 2016
SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line
M Seifi-Najmi, M Hajivalili, R Safaralizadeh, et al.
Page
of 4